Literature DB >> 8733940

Effect of MCI-186 on postischemic reperfusion injury in isolated rat heart.

U Minhaz1, M Tanaka, H Tsukamoto, K Watanabe, S Koide, A Shohtsu, H Nakazawa.   

Abstract

MCI-186 (3-methyl-1-phenyl-2-pyrazolin-5-one) is a newly developed antioxidant which has been shown to reduce brain edema in cerebral ischemia through inhibition of the lipoxygenase pathway of arachidonic acid. However, its effect on myocardial reperfusion injury after prolonged ischemia has not yet been demonstrated. We compared the mode of the effect of MIC-186 and recombinant human CuZn superoxide dismutase (rh-SOD) in isolated perfused rat hearts subjected to 60-min ischemia followed by 60-min reperfusion. Left ventricular developed pressure (LVDP), necrotic area and the release of creatine phosphokinase (CPK) and endogenous CuZn superoxide dismutase (endoge-SOD) were measured to evaluate myocardial damage. The decrease in left coronary flow (CBF) was measured as an index of the damage of left coronary circulation. MCI-186 (14.5 mg/L) was perfused for 10 min in the MCI group and rh-SOD (70 mg/L) was perfused during the reperfusion period in the SOD group starting 5 min prior to reperfusion. The release patterns of CPK and endoge-SOD were analyzed to elucidate the difference in the mode of protection of MCI-186 and rh-SOD. The LVDP remained higher in both MCI and SOD groups than that of control (76 +/- 1, 77 +/- 2 and 69 +/- 1% of preischemic value, respectively). The necrotic area was significantly attenuated in both MCI and SOD groups compared with that in the control group (16 +/- 1, 14 +/- 1 and 32 +/- 1%, respectively, p < 0.05). Total CPK release was lower in both MCI and SOD groups than in the control (78 +/- 7, 100 +/- 2 and 116 +/- 4 x 10(3) units/g myocardium respectively). The decrease in CPK release was more marked in the MCI group than that in the SOD group (p < 0.05). The reduction in CBF was significantly attenuated by the treatment with rh-SOD or MCI-186, but the effect was much higher in the SOD group than in the MCI group (69 +/- 5, 58 +/- 2, and 48 +/- 2% in SOD, MCI and control groups, respectively). The release pattern of endoge-SOD was identical to that of CPK and thus this did not distinguish the mode of effect of MCI-186 from that of rh-SOD. These results indicate that MCI-186 reduces reperfusion injury in isolated perfused hearts with prolonged ischemia and the effect is more closely related to the reduction of myocyte damage than the preservation of the coronary circulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8733940     DOI: 10.3109/10715769609088034

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  13 in total

1.  Hydrogen-rich saline solution attenuates renal ischemia-reperfusion injury.

Authors:  Chihiro Shingu; Hironori Koga; Satoshi Hagiwara; Shigekiyo Matsumoto; Koji Goto; Isao Yokoi; Takayuki Noguchi
Journal:  J Anesth       Date:  2010-05-18       Impact factor: 2.078

2.  Effect of a novel free radical scavenger, edaravone, on puromycin aminonucleoside induced nephrosis in rats.

Authors:  Tomonosuke Someya; Kazunari Kaneko; Toshiyuki Yamada; Yuichiro Yamashiro
Journal:  Pediatr Nephrol       Date:  2005-08-04       Impact factor: 3.714

3.  Protective effect of edaravone against hypoxia-reoxygenation injury in rabbit cardiomyocytes.

Authors:  Masahiro Yamawaki; Norihito Sasaki; Masaki Shimoyama; Junichiro Miake; Kazuhide Ogino; Osamu Igawa; Fumito Tajima; Chiaki Shigemasa; Ichiro Hisatome
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

4.  Beyond free radical scavenging: Beneficial effects of edaravone (Radicut) in various diseases (Review).

Authors:  Kiyoshi Kikuchi; Nobuyuki Takeshige; Naoki Miura; Yoko Morimoto; Takashi Ito; Salunya Tancharoen; Kei Miyata; Chiemi Kikuchi; Narumi Iida; Hisaaki Uchikado; Naohisa Miyagi; Naoto Shiomi; Terukazu Kuramoto; Ikuro Maruyama; Motohiro Morioka; Ko-Ichi Kawahara
Journal:  Exp Ther Med       Date:  2011-09-20       Impact factor: 2.447

5.  A new free radical scavenger, edaravone, ameliorates oxidative liver damage due to ischemia-reperfusion in vitro and in vivo.

Authors:  Tomoya Abe; Michiaki Unno; Heigo Takeuchi; Tetsuya Kakita; Yu Katayose; Toshiki Rikiyama; Takanori Morikawa; Masanori Suzuki; Seiki Matsuno
Journal:  J Gastrointest Surg       Date:  2004 Jul-Aug       Impact factor: 3.452

6.  Inhibitory effects of edaravone on the production of tumor necrosis factor-alpha in the isolated heart undergoing ischemia and reperfusion.

Authors:  Shunji Onimaru; Kazuo Nakamura; Hiroko Kariyazono; Ryuji Ikeda; Takayuki Ueno; Yoshihiro Fukumoto; Akira Yabuki; Ryuzo Sakata; Katsushi Yamada
Journal:  Heart Vessels       Date:  2006-03       Impact factor: 2.037

7.  Antifibrotic effect of edaravone in rat liver cirrhosis induced by dimethylnitrosamine.

Authors:  Hiroto Tanaka; Hiroki Ueda; Hiroko Fukuchi; Masakazu Ichinose
Journal:  Clin Exp Med       Date:  2009-03-04       Impact factor: 3.984

8.  Effect of edaravone, a novel free radical scavenger, supplemented to cardioplegia on myocardial function after cardioplegic arrest: in vitro study of isolated rat heart.

Authors:  Kazuhiro Yamazaki; Senri Miwa; Shinya Toyokuni; Shintaro Nemoto; Wnimunk Oriyanhan; Kiyoaki Takaba; Yoshiaki Saji; Akira Marui; Takeshi Nishina; Tadashi Ikeda; Masashi Komeda
Journal:  Heart Vessels       Date:  2009-05-24       Impact factor: 2.037

9.  Chemical repair activity of free radical scavenger edaravone: reduction reactions with dGMP hydroxyl radical adducts and suppression of base lesions and AP sites on irradiated plasmid DNA.

Authors:  Kuniki Hata; Ayumi Urushibara; Shinichi Yamashita; Mingzhang Lin; Yusa Muroya; Naoya Shikazono; Akinari Yokoya; Haiying Fu; Yosuke Katsumura
Journal:  J Radiat Res       Date:  2014-09-11       Impact factor: 2.724

10.  Status of systemic oxidative stress during therapeutic hypothermia in patients with post-cardiac arrest syndrome.

Authors:  Kenji Dohi; Kazuyuki Miyamoto; Kenichiro Fukuda; Shunsuke Nakamura; Munetaka Hayashi; Hirokazu Ohtaki; Seiji Shioda; Tohru Aruga
Journal:  Oxid Med Cell Longev       Date:  2013-08-26       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.